查找临床试验
已按「血友病」检索，对应国际通用词 hemophilia
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
United States、Taiwan
年龄 12 Years – 不限
Sanofi
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
China
年龄 12 Years – 18 Years
Institute of Hematology & Blood Diseases Hospital, China
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
United States、Canada、Japan、Taiwan
年龄 12 Years – 不限
Sanofi
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
China
年龄 18 Years – 65 Years
Institute of Hematology & Blood Diseases Hospital, China
A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
Taiwan
年龄 不限 – 不限
Tri-Service General Hospital (TSGH)
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
China
年龄 0 Years – 18 Years
Runhui WU
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
United States、Belgium、Brazil、Canada、China 等 12 国
年龄 1 Year – 11 Years
Sanofi
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
Taiwan
年龄 不限 – 不限
Sanofi
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
United States、Argentina、Australia、Austria、Brazil 等 12 国
年龄 1 Year – 17 Years
Pfizer
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
China
年龄 18 Years – 不限
Shanghai Xinzhi BioMed Co., Ltd.